Featured articles

Other articles

Newormics launches new vivoChips for early stage worms
Early larval stages of C. elegans (L1 to L3 and Dauer) have always been among the hardest to immobilize and . . .

READ MORE →


Newormics awarded an SBIR Phase I grant from the NIEHS
Newormics was awarded an SBIR Phase I grant from the National Institute of Environmental Health Sciences (NIEHS) for the project . . .

READ MORE →


Newormics at the 2019 International C. elegans Conference
Newormics is exhibiting at the 22nd International C. elegans Conference at UCLA, Los Angeles from 20th June – 24th June. . . .

READ MORE →


Newormics selected for the NIH I-Corps
Newormics was selected for the NIH I-Corps April-June 2019 cohort. Over the course of the I-Corps program, the team had . . .

READ MORE →


Newormics awarded SBIR Phase I grant from the NIMH
Newormics was awarded an SBIR Phase I grant from the National Institute of Mental Health (NIMH) for the project “A . . .

READ MORE →


Introducing the Next Generation Drug Discovery Platforms
Newormics is a developer of the first high-throughput, high-content drug screening platforms for use with in vivo small animal models . . .

READ MORE →